Race for Coronavirus Vaccine Faces Early Challenges

In The Hill, Catalyst’s Jeff Myers argues it’s unlikely early COVID-19 treatments will have remarkably high efficacy, but it’s still worth making and having them be available options to combat the deadly coronavirus. “I think the first drug out of the chute is not going to be a magic bullet; it’s going to be a start,” he said. “But you’re more likely to get products that can treat symptoms way faster than you’re going to get a vaccine.”

Recent Tweets

This is fantastic news Proteus Team! Congrats to you and TennCare. As the importance of remote monitoring is realized- especially during and immediately following this COVID pandemic, TennCare will be seen as an early adopter. This will be an important…https://lnkd.in/erD_A2G

FDA continues working around the clock to combat the #COVID19 pandemic. Here is our latest update: https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-daily-roundup-april-14-2020

In @AISHealth, Catalyst’s Jeff Myers weighs in on the #SCOTUS 8-1 ruling of #CMS owing billions to health insurers in risk corridor funding, discussing while it’s mandated by law, the risk corridor program isn’t well designed to begin with. http://catalysthcc.com/2020/05/04/health-insurers-hail-scotus-ruling-in-risk-corridors-case/

In @thehill, Catalyst’s Jeff Myers argues it’s unlikely early #COVID19 treatments will have remarkably high efficacy, but it’s still worth making and having them be available options to combat the deadly #coronavirus. https://thehill.com/policy/healthcare/494936-race-for-coronavirus-vaccine-faces-early-challenges